Journal Article

Gene- and cell-based therapies for cardiovascular diseases: current status and future directions

L.G Melo, M Gnecchi, A.S Pachori, K Wang and V.J Dzau

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 6, issue suppl_E, pages E24-E35
Published in print September 2004 | ISSN: 1520-765X
Published online September 2004 | e-ISSN: 1554-2815 | DOI:
Gene- and cell-based therapies for cardiovascular diseases: current status and future directions

Show Summary Details


Recent advances in understanding the molecular and cellular basis of cardiovascular diseases, together with the availability of tools for genetic manipulation of the cardiovascular system, offer possibilities for new treatments. Gene therapies have demonstrated potential usefulness in treating complex diseases such as hypertension, atherosclerosis and myocardial ischaemia based on studies of various animal models. Some of these experimental therapies have transitioned into clinical trials to assess their safety, feasibility and therapeutic potential in humans with cardiovascular disease. The recent isolation of adult progenitor cells with the capacity to differentiate into endothelial and cardiomyocyte phenotypes has opened an exciting era of cell therapies for vascularization and repair of ischaemic tissues and injured blood vessels. Despite these significant developments, we believe that the successful translation of these experimental therapies into clinical practice will require safer and more effective vectors and delivery tools, a deeper knowledge of progenitor cell biology and, finally, the documentation of efficacy and safety through multicentre randomized trials.

Keywords: Bone marrow; Cardiac progenitors; Cellular cardiomyoplasty; Coronary artery disease; Endothelial progenitor cells; Heme oxygenase; Protective gene therapy

Journal Article.  10350 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.